Spondyloarthritis & psoriatic arthritis
Responsiveness and Minimum Clinically Important Difference in Patient‐Reported Outcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study
Authors' conclusion
SRMs and MCII were relatively small in this real-world population, particularly among those with lower disease activity at baseline. BASDAI, cDAPSA, and PsAID12 had good sensitivity to change
Study context
- Population
- Patients with psoriatic arthritis (PsA) starting therapy (mean age 51 years, 53% female), PsA Research Consortium266 therapy courses
- Participants
- 171 patients
- Exposure
- Moderate to highly active PsA vs lower disease activity at baseline
- Outcome
- Responsiveness to therapy (SRM) and MCII of patient-reported outcome measures
Methodological detailslongitudinal, PsA Research Consortium
- Longitudinal
- PsA Research Consortium
Main finding
As reported in the abstract
SRMs and MCII of patient-reported outcome measures
- Standardized response means (SRMs) and minimum clinically important improvement (MCII) for all measures were small to moderate, although greater among those with higher baseline disease activity
- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) had the best SRM overall and for less active PsA
- Clinical Disease Activity of PsA (cDAPSA) and PsAID12 were best for those with higher disease activity
Observational data: associations, not effects.
Original publication
Responsiveness and Minimum Clinically Important Difference in Patient‐Reported Outcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study. Arthritis Care Res (Hoboken). Published 26 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →